Earnings Results: Amgen stock jumps after record earnings beat expectations, and biotech raises full-year outlook
Shares of Amgen Inc. jumped in after-hours trading Thursday, after the biotechnology giant reported record second-quarter earnings that rose above expectations and raised the full-year outlook, as volume growth offset a slight decline in prices. “We had a very strong quarter, serving more patients…#amgeninc #robertbradway #amgn #prolia #aranesp #parsabiv #neulasta #eps (Source: Reuters: Health)
Source: Reuters: Health - August 3, 2023 Category: Consumer Health News Source Type: news
Safety, Efficacy of Vadadustat Explored for CKD
THURSDAY, April 29, 2021 -- Vadadustat met the noninferiority criteria for cardiovascular safety versus darbepoetin alfa among patients with dialysis-dependent chronic kidney disease (DD-CKD), but not those with non-DD-CKD (NDD-CKD), according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 29, 2021 Category: Pharmaceuticals Source Type: news
Aranesp (Darbepoetin Alfa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 22, 2017 Category: Drugs & Pharmacology Source Type: news
Amgen And DaVita Enter Into New Sourcing And Supply Agreement
THOUSAND OAKS, Calif., Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc. This is a continuation of Amgen's long-term relationship with DaVita that is focused on serving dialysis patients.
Under the terms of the new agreement, Amgen will supply DaVita with EPOGEN® (epoetin alfa) and Aranesp® (darbepoetin alfa) in amounts necessary to meet a specified annual percentage of DaVita's and its affiliates' requirements for erythropoiesis-stimulating agents used in providing dialysis services in the United States and Puerto Rico. The...
Source: Amgen News Release - January 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association
BLINCYTO® (Blinatumomab) TOWER Study Demonstrates Improved Overall Survival Versus Standard of Care in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
TOWER Study to be Presented at Presidential Symposium as a Best Abstract
Sub-group Analyses From Pivotal Head-To-Head Phase 3 Studies Provide Further Insight Into Kyprolis® (Carfilzomib) as Treatment Option for Patients With Multiple Myeloma
Aranesp® (Darbepoetin Alfa) Phase 3 ARCADE Data Demonstrates Significant Reduction in Red Blood Cell Transfusions in Anemic Patients With Myelodysplastic Syndrome
THOUSAND OAKS, Calif., May 19, 2016 /PRNewswire/...
Source: Amgen News Release - May 19, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
First Quarter 2016 GAAP EPS Were $2.50
2016 Total Revenues and Adjusted EPS Guidance Increased to $22.2-$22.6 Billion and $10.85-$11.20, Respectively
THOUSAND OAKS, Calif., April 28, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2016. Key results include:
Total revenues increased 10 percent versus the first quarter of 2015 to $5,527 million, with 7 percent product sales growth driven by Enbrel® (etanercept), Prolia® (denosumab), Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), Kyprolis® (carfilzomib) and XGEVA® (denosumab).
Adjusted EPS grew 1...
Source: Amgen News Release - April 28, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Why Your Oncologist Might Prescribe Procrit or...
Learn why doctors prescribe Procrit and Aranesp to boost red cell production in breast cancer patients who have anemia after undergoing chemotherapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - April 18, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
How are Procrit & Aranesp Used to Treat...
Procrit and Aranesp help boost red cell production for breast cancer patients who have anemia after undergoing chemotherapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 28, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
First Phase 3 Data From Placebo-Controlled Study With an Erythropoiesis-Stimulating Agent (ESA) in Anemic Patients With MDS
Study Met Primary Endpoint and Key Secondary Endpoint of Erythroid Response
THOUSAND OAKS, Calif., Feb. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk MDS at the end of the blinded 25-week study period. Aranesp also significantly improved erythro...
Source: Amgen News Release - February 15, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen to pay $71 million to settle claims of off-label drug uses
Biotechnology company Amgen Inc. has agreed to pay $71 million to 48 states and the District of Columbia to settle claims that it improperly promoted its top-selling drugs, Aranesp and Enbrel, for uses not approved by the Food and Drug Administration.
California will receive $4.6 million from the settlement, Attorney General Kamala Harris announced Tuesday.
Harris and the other attorneys general alleged that Amgen (Nasdaq: AMGN) violated state consumer protection laws by promoting Aranesp for dosing… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2015 Category: Pharmaceuticals Source Type: news
Texas to share in $71M California pharma company settlement
The State of Texas will build up its bank account as a result of Thousand Oaks, California-based Amgen Inc.’s decision to settle a multi-state investigation stemming from allegations it unlawfully promoted biologic medications Aranesp and Enbrel for off-label uses.
Amgen has agreed to pay $71 million to 49 states, including Texas, to resolve the matter, according to Texas Attorney General Ken Paxton. Texas’ share of the settlement is $4.3 million.
Aranesp is a treatment for anemia, and Enbrel… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2015 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news
Amgen Pays $71 Mln to Settle Enbrel, Aranesp Marketing CaseAmgen Pays $71 Mln to Settle Enbrel, Aranesp Marketing Case
Amgen Inc has reached a $71 million settlement with 48 states and the District of Columbia to resolve claims that the company promoted its drugs Enbrel and Aranesp for uses not approved by the FDA. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 19, 2015 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
Amgen to Pay $71M to Settle Off-Label Enbrel, Aranesp Claims
California-based biotech Amgen has agreed to pay $71 million to resolve claims that the company promoted its popular Enbrel and Aranesp drugs for uses not approved by the FDA. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 19, 2015 Category: Pharmaceuticals Source Type: news
